45 results about "Tamoxifen Citrate" patented technology

The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein aggregate (“APA”) compound selected from the group consisting of pimozide, fluphenazine (e.g., fluphenazine hydrochloride), tamoxifen (e.g., tamoxifen citrate), taxol, cantharidin, cantharidic acid, salts thereof and their structurally related compounds. It is based, at least in part, on the discovery that each of the aforelisted compounds were able to promote degradation of aggregated ATZ protein in a Caenorhabditis elegans model system. According to the invention, treatment with one or more of these APA compounds may be used to ameliorate the symptoms and signs of AT deficiency as well as other disorders marked by protein aggregation, including, but not limited to, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.

The invention relates to a preparation method of tamoxifen citrate polylactic acid-glycolic acid copolymer microspheres. The method comprises the following steps: 1) dissolving polylactic acid-glycolic acid copolymer (PLGA) in an organic solvent, adding tamoxifen citrate, and dissolving under ultrasonic action to obtain a solution as organic phase; 2) adding slowly the organic phase into aqueous solution of polyvinyl alcohol (PVA) as water phase under stirring, adding electrolytes, stirring at room temperature until the organic solvent volatilizes completely, centrifugating, washing, and freeze-drying to obtain tamoxifen citrate polylactic acid-glycolic acid copolymer microspheres. The microsphere has round shape, uniform particle size distribution (below 10 micrometers), high drug content (above 10%), high encapsulation rate (about 80%), and in vitro release characteristics of long-acting preparations; and is suitable for the use as implant for prevention and treatment of breast cancer.

The invention relates to tamoxifen citrate tablets which are prepared by the following steps: firstly, preparing tamoxifen citrate to inclusion compounds; and then, preparing the tablets.

The invention relates to controlled-release lincomycin granules. Firstly, tamoxifen citrate is prepared into a clathrate compound and then the clathrate compound is prepared into the controlled-release granules.

The invention relates to tamoxifen citrate sustained-release tablets, the preparation method of which comprises the steps of preparing tamoxifen citrates into clathrate compounds and further preparing the clathrate compounds into sustained-release tablets.

The invention discloses a polypeptide hydrogel scaffold loaded with drugs and fat-derived mesenchymal stem cells and a preparation method thereof. (1) Use ultrapure water to prepare a tamoxifen citrate solution with a concentration of 1.836×10‑5M~2.651×10‑5M; (2) form a culture plate containing 1.836×10‑5M~2.651×10‑5M The polypeptide hydrogel of 5M tamoxifen citrate; (3) the tamoxifen citrate solution containing 1.836×10‑5M~2.651×10‑5M in the polypeptide hydrogel in the washing step (2) The pH of the solution was 7.0; (4) Take human adipose-derived mesenchymal stem cells at 1.0×105 cells / ml and add 500 μl to each well. After culturing for 3 days, a polypeptide hydrogel scaffold loaded with drugs and adipose-derived mesenchymal stem cells was obtained. The polypeptide hydrogel scaffold of the present invention contains both the anticancer drug tamoxifen citrate and human adipose-derived mesenchymal stem cells, and can be used to construct living tissues.

The invention relates to a tamoxifen citrate freeze-dried powder injection which comprises tamoxifen citrate, a composition of sorbitol, dextran and lactose in a weight ratio of 3.2:5.5:2, a composition of arginine and glutathione in a weight ratio of 1.6:5.7, and disodium ethylenediamine tetraacetate.

The invention provides a preparation method of a tamoxifen citrate E isomer, which comprises the following steps: 1) with an intermediate for preparing tamoxifen citrate and having a structural formula as shown in the formula I as a raw material, performing a dehydration reaction in an acid condition in a mixed solution of water and organic solvent at certain proportion to obtain a mixture of an intermediate 1 with a structural formula as shown in the formula II and an intermediate 2 with a structural formula as shown in the formula III; 2) in an organic solvent of certain amount, enabling the intermediate 1 and the intermediate 2 to react with citric acid or hydrate thereof, and cooling for crystallization to obtain a mixture of Z-tamoxifen citrate with a structural formula as shown in the formula IV and E-tamoxifen citrate with a structural formula as shown in the formula V; and 3) in the water and organic solvent at certain proportion, performing twice recrystallization of the mixture of Z-tamoxifen citrate and E-tamoxifen citrate. The method provided by the invention can be used for preparing a high-purity tamoxifen citrate E isomer, provides an impurity reference substance for the National Institutes for Food and Drug Control, and solves the problem in E-isomer detection in a practical production process.